Vildagliptin
|
|
|
- CAS-Nr.
- 274901-16-5
- Englisch Name:
- Vildagliptin
- Synonyma:
- Galvus;Vigliptin;Vildgliptin;Vildagliptin (LAF-237);LAF237; GALVUS; NVP-LAF 237; ZOMELIS;1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine;(2S)-1-(2-((3-hydroxyadaMantan-1-yl)aMino)acetyl)pyrrolidine-2-carbonitrile;(-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1[3,7]]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile;dagL;Laf 237
- CBNumber:
- CB71449010
- Summenformel:
- C17H25N3O2
- Molgewicht:
- 303.4
- MOL-Datei:
- 274901-16-5.mol
|
Vildagliptin Eigenschaften
- Schmelzpunkt:
- 153-155?C
- alpha
- -78.3° (c = 9.73 in methanol)
- Siedepunkt:
- 531.3±50.0 °C(Predicted)
- Dichte
- 1.27
- Flammpunkt:
- 275.1℃
- storage temp.
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- L?slichkeit
- Soluble in DMSO (up to 45 mg/ml), in DMF (up to 20 mg/ml), or in Ethanol (up to 20 mg/ml).
- Aggregatzustand
- solid
- pka
- 15.05±0.40(Predicted)
- Farbe
- White
- Stabilit?t:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF, or ethanol may be stored at -20°C for up to 3 months
- InChI
- InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
- InChIKey
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N
- SMILES
- N1(C(CNC23CC4CC(CC(O)(C4)C2)C3)=O)CCC[C@H]1C#N
- CAS Datenbank
- 274901-16-5(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H332 |
Gesundheitssch?dlich bei Einatmen. |
Akute Toxizit?t inhalativ |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P271, P304+P340, P312 |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Vildagliptin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC
50=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.
Chemische Eigenschaften
White Solid
Verwenden
Labelled Vildagliptin. It is a new oral anti-hyperglycemic agent of a new dipeptidyl peptidase-IV (DPP-IV) inhibitor class of drugs. Antidiabetic.
Nebenwirkungen
The most common adverse events reported in patients receiving vildagliptin included headache, nasopharyngitis, cough, constipation, dizziness, and increased sweating. Vildagliptin is not recommended for patients with liver impairment.
Vildagliptin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Vildagliptin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 607)Lieferanten
274901-16-5()Verwandte Suche:
- Vidagliptin (see vildagliptin)
- Vildagliptin
- 1-[2-(3-HydroxyadaMant-1-ylaMino)acetyl]pyrrolidine-2(S)-carbonitrile
- (S)-1-[2-((5S,7S)-3-hydroxy-adaMantan-1-ylaMino)-acetyl]-pyrrolidine-2-carbonitrile
- NVP-LAF 237
- ZoMelis
- Vildagliptin API
- Vildagliptin (NVP-LAF 237)
- 2-Pyrrolidinecarbonitrile, 1-(((3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)amino)acetyl)-, (2S)-
- Laf 237
- Unii-I6B4B2U96p
- 2-Pyrrolidinecarbonitrile,1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)aMino]acetyl]-, (2S)-
- Vildagliptin (-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile
- Vildaliptin
- Vildagliptin 2-Pyrrolidinecarbonitrile,1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-,
- (S)-1-[2-[(3-Hydroxyadamant-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile
- pharma API Vildagliptin
- Vildagliptin 、VildagliptinAPI
- Best Quality Vildagliptin with best price CAS NO.274901-16-5
- China Top quality CAS:274901-16-5 Vildagliptin CAS NO.274901-16-5
- Top quality API Vildagliptin with best price
- API Vildagliptin CAS 274901-16-5
- pharma API cas 274901-16-5 Vildagliptin
- VILDAGLIPTIN CAS NO:274901-16-5
- Vildagliptin, 97%, DPP-4 inhibitor
- ethyl {2-amino-6-[(4-fluorobenzyl)amino]pyridin-3-yl}carbamate (2Z)-but-2-enedioate
- (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]-acetyl]-pyrrolidin-2-carbonitrile
- dagL
- (2S)-1-((3-Hydroxyadamantan-1-yl)glycyl)pyrrolidine-2-carbonitrile
- (-)-(2S)-1-[[(3-Hydroxytricyclo [3.3.1.1[3,7]]dec-1-yl)amino] acetyl]pyrrolidine-2-carbonitrile
- Vildagliptin USP/EP/BP
- Vildagliptin (API)
2-Pyrrolidinecarbonitrile,1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-,
- DSP7238
- VildagliptinQ: What is
Vildagliptin Q: What is the CAS Number of
Vildagliptin Q: What is the storage condition of
Vildagliptin Q: What are the applications of
Vildagliptin
- Vildagliptin Supplier
- (2S)-1-(2-((3-hydroxyadaMantan-1-yl)aMino)acetyl)pyrrolidine-2-carbonitrile
- Vildagliptin (LAF-237)
- Vildgliptin
- (-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1[3,7]]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile
- Galvus
- 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine
- LAF237; GALVUS; NVP-LAF 237; ZOMELIS
- Vigliptin
- Vader column dean
- Vildagliptin IP/In-House
- Viggliptin
- Vildagliptin In-House
- Vildagliptin Crude
- Vildagliptin
(2S)-1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]- 2-pyrrolidinecarbonitrile
- (S)-1-(2-(((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
- Vildagliptin -HIS
- Vidaletin
- (S)-1-[2-(3-Hydroxy-adamantan-1-ylamino)-acetyl]-pyrrolidine-2-carbonitrile
- 274901-16-5
- C17H22D3N3O2
- C23H33N3O8
- C18H20F6N3O5P
- Galvus
